Market Intelligence, Clinical Progress, and High-Purity Reagents for Apoptosis Modulation, Oncology, and Cell Therapy Safety Switch Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CASP9 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme (p35/p10 Heterodimer) | Caspase-9 active form, high purity (>95%), endotoxin <1EU/µg, sequence verified. | View CASP9 Products |
| Proenzyme (Full-length Zymogen) | Procaspase-9 (residues 1-416), HEK293 expressed, inactive monomer for autoprocessing studies. | View CASP9 Products |
| Mutant Control (C287A Catalytically Dead) | Site-directed mutant for dominant negative assays and specificity controls. | View CASP9 Products |
| Mutant Protein (Disease-Associated Variants) | CASP9/p35/p10 with specific mutations (e.g., dbSNP rs1052571, rs4646008, rs2308941), high purity, sequence verified. | View CASP9 Products |
| Gene Delivery (ORF Lentivirus) | Full-length ORF for stable cell line construction in cancer models. | View CASP9 Products |
| Benchmark Antibody (Cleaved Form Specific) | Recombinant positive control for p35/p10 detection. | View CASP9 Products |
| Validator (siRNA Set) | For knockdown verification and specificity confirmation in apoptosis assays. | View CASP9 Products |
| Related Target: APAF1 (CARD Domain) | Essential scaffold for apoptosome formation and Caspase-9 recruitment. | View APAF1 Products |
| Related Target: CASP3 | Downstream executioner caspase for functional readouts and selectivity assays. | View CASP3 Products |
| Related Target: XIAP (BIR3 Domain) | Endogenous inhibitor of Caspase-9, for counter-screening and negative control. | View XIAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subunit Activity Differentiation | Recombinant p35/p10 cleaved forms available with high structural fidelity. |
| Homolog Off-Target Screening | Full panel of initiator/executioner caspases strictly verified by mass spec. |
| Lack of Controls | Clinical Benchmark Antibodies included for cleavage validation. |
| False Positives | Validated siRNA included for specificity checks in cell-based assays. |
| Enzyme Activity Standardization | Pre-formed p35/p10 heterodimer with defined specific activity, minimal batch variation. |
| Zymogen Activation Mechanism | Full-length Procaspase-9 with intact pro-domain, verified by mass spectrometry. |
| Apoptosome Complex Assembly | APAF1 CARD domain available for binding studies; compatible with Co-IP and SPR. |
| Cross-Caspase Selectivity | Homolog panel: Caspase-3, Caspase-8 for off-target liability screening. |
Live CASP9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CASP9-targeted therapeutics is intensifying, with major players shifting focus from traditional apoptosis inhibitors to inducible Caspase-9 (iCasp9) suicide gene systems for CAR-T and cell therapy safety switches. Concurrently, SMAC mimetics (IAP inhibitors) and pan-caspase inhibitor programs for non-oncology indications (e.g., NASH, acute liver failure) are driving renewed demand for high-fidelity CASP9 reagents. As resistance mechanisms to BCL-2 inhibitors (Venetoclax) emerge, R&D is increasingly targeting the apoptosome assembly checkpoint, positioning CASP9 as a critical biomarker and mechanistic target for next-generation combination therapies. The next wave of R&D is targeting highly responsive, orthogonal dimerization-activated CASP9 constructs to manage cytokine release syndrome and off-tumor toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-Caspase Inhibitors & Small Molecules | Novartis, Sanofi, Conatus | Liver Disease (NASH/ASH), Neurodegeneration, Ischemia | Selectivity Panel (Need active CASP9 vs CASP3/8 for isoform selectivity) |
| SMAC Mimetics (IAP Inhibitors) | Bristol Myers Squibb, AstraZeneca | Solid Tumors, Hematologic Cancers | Apoptosome Assembly Assay (Need CASP9 + APAF1 proteins) |
| Peptidomimetic Modulators | Academic / Discovery Phase | Neurodegeneration | Dimerization Disruption Assay (Need CASP9 monomer/dimer forms) |
| Gene Therapy (iCasp9) | Bellicum, Autolus, Cell Therapy Partners | CAR-T / Cell Therapy Safety | Dimerization Assay (Need high-purity recombinant mutants) |
| Gene Editing | Academic R&D | Solid Tumors | Functional Knockdown (Need sequence-verified lentivirus) |